Phase i study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 803-810

  Pavlick, Anna C ^a   Wu, Jennifer ^a   Roberts, John ^c   Rosenthal, Mark A ^a   Hamilton, Anne ^a   Wadler, Scott ^b   Farrell, Kathleen ^a   Carr, Michelle ^a   Fry, David ^a   Murgo, Anthony J ^d   Oratz, Ruth ^a   Hochster, Howard ^a   Liebes, Leonard ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bryostatin 1; Cisplatin; Melanoma; Protein kinase C

Indexed keywords

ANTIEMETIC AGENT; BRYOSTATIN 1; CISPLATIN; PROTEIN KINASE C;

ADULT; AGED; APPENDIX TUMOR; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DEHYDRATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS TUMOR; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK TUMOR; HEADACHE; HUMAN; INFECTION; KIDNEY TUMOR; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVARY TUMOR; PANCREAS TUMOR; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SARCOMA; SIGNAL TRANSDUCTION; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRYOSTATINS; CISPLATIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE C;

EID: 68149132488     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0931-y     Document Type: Article

References (41)

1. SE Aeder PM Martin JW Soh IM Hussaini 2004 PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways Oncogene 23 9062 9069
2. A Basu JS Lazo 1992 Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1 Cancer Res 52 3119 3124
3. AH Corbett AW Fernald N Osheroff 1993 Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation Biochemistry 32 2090 2097
4. IL Dale TD Bradshaw A Gescher GR Pettit 1989 Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells Cancer Res 49 3242 3245 (Pubitemid 19162131)
5. BF El-Rayes S Gadgeel AF Shields S Manza P Lorusso PA Philip 2006 Phase I study of bryostatin 1 and gemcitabine Clin Cancer Res 12 7059 7062
6. JM Ford WN Hait 1990 Pharmacology of drugs that alter multidrug resistance in cancer Pharmacol Rev 42 155 199
7. JE Goodnight Jr HS Moseley FR Eilber G Sarna DL Morton 1979 Cis-dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma Cancer Treat Rep 63 2005 2007
8. Grunicke H, Hofmann J, Maly K, Goddard PM, Kelland LR, Morgan SE (1991) Enhancement of the antiproliferative effect of cis-diammine-dichloroplatinum (II) and other antitumor agents by inhibition of enzymes involved in growth factor signal transduction. In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, New York, pp 161-172
9. H Grunicke J Hofmann I Utz F Uberall 1994 Role of protein kinases in antitumor drug resistance Ann Hematol 69 S1 S6
10. HH Grunicke F Uberall 1992 Protein kinase C modulation Semin Cancer Biol 3 351 360
11. M Gschwendt G Furstenberger S Rose-John M Rogers W Kittstein GR Pettit CL Herald F Marks 1988 Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro Carcinogenesis 9 555 562
12. M Gschwendt H Leibersperger W Kittstein F Marks 1992 Protein kinase C zeta and eta in murine epidermis. TPA induces down-regulation of PKC eta but not PKC zeta FEBS Lett 307 151 155
13. DE Hallahan S Virudachalam ML Sherman E Huberman DW Kufe RR Weichselbaum 1991 Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation Cancer Res 51 4565 4569
14. PF Hickman GJ Kemp CH Thompson AJ Salisbury K Wade AL Harris GK Radda 1995 Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic spectroscopic study Br J Cancer 72 998 1003
15. H Hochster L Liebes J Speyer J Sorich B Taubes R Oratz J Wernz A Chachoua B Raphael RZ Vinci 1994 Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen J Clin Oncol 12 553 559
16. J Hofmann W Doppler A Jakob K Maly L Posch F Uberall HH Grunicke 1988 Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C Int J Cancer 42 382 388
17. RL Hornung JW Pearson M Beckwith DL Longo 1992 Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity Cancer Res 52 101 107
18. S Isonishi PA Andrews SB Howell 1990 Increased sensitivity to cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate J Biol Chem 265 3623 3627
19. DN Jackson DA Foster 2004 The enigmatic protein kinase C delta: complex roles in cell proliferation and survival FASEB J 18 627 636
20. GC Jayson D Crowther J Prendiville AT McGown C Schneid P Stern R Young P Brenchley J Chang S Owens 1995 A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion Br J Cancer 72 461 468
21. L Liebes M Potmesil T Kim D Pease M Buckley D Fry J Cho H Adler K Dar A Zeleniuch-Jacquotte H Hochster 1998 Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan Clin Can Res 4 545 557
22. PA Masso-Welch JS Winston S Edge KM Darcy H Asch MM Vaughan MM Ip 2001 Altered expression and localization of PKC eta in human breast tumors Breast Cancer Res Treat 68 211 223
23. RM Mohammad H Diwakaran A Maki MA Emara GR Pettit B Redman A AL-Katib 1995 Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma Leuk Res 19 667 673
24. F Nezhat S Wadler F Muggia J Mandeli G Goldberg J Rahaman C Runowicz AJ Murgo GJ Gardner 2004 Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study Gynecol Oncol 93 144 148
25. 2+-independent isoform of protein kinase C in epithelial tissues, in association with epithelial differentiation Cell Growth Diff 4 167 175
26. P Perego G Casati RA Gambetta C Soranzo F Zunino 1993 Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells Cancer Lett 72 53 58
27. GR Pettit CL Herald DL Doubek DL Herald E Arnold J Clardy 1982 Isolation and structure of bryostatin 1 J Am Chem Soc 104 6846 6848
28. Philip PA, Harris AL (1995) Potential for protein kinase C inhibitors in cancer therapy. In: Muggia FM (ed) Concepts, mechanisms and new targets for chemotherapy, 1st edn. Kluwer, Boston, pp 3-28
29. PA Philip D Rea P Thavasu J Carmichael NSA Stuart H Rockett DC Talbot T Ganesan GR Pettit F Balkwill AL Harris 1993 Phase I study of Bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo J Natl Cancer Inst 85 1812 1818
30. IF Pollack S Kawecki JS Lazo 1996 Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor J Neurosurg 84 1024 1032
31. J Prendiville D Crowther N Thatcher PJ Woll BW Fox A McGown N Testa P Stern R McDermott M Potter GR Pettit 1993 A phase I study of intravenous bryostatin 1 in patients with advanced cancer Br J Cancer 68 418 424
32. JD Roberts MR Smith EJ Feldman L Cragg MM Millenson GJ Roboz C Honeycutt R Thune K Padavic-Shaller WH Carter V Ramakrishnan AJ Murgo S Grant 2006 Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma Clin Cancer Res 12 5809 5816
33. LM Schuchter AH Esa S May MK Laulis GR Pettit AD Hess 1991 Successful treatment of murine melanoma with bryostatin 1 Cancer Res 51 682 687
34. Z Szallasi L Du R Levine NE Lewin PN Nguyen MD Williams GR Pettit PM Blumberg 1996 The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1 Cancer Res 56 2105 2111
35. CH Thompson VM Macaulay KJ O'Byrne GJ Kemp SM Wilner DC Talbot AL Harris GK Radda 1996 Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply Br J Cancer 73 1161 1165
36. G Trenn GR Pettit H Takayama J Hu-Li MV Sitkovsky 1988 Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins J Immunol 140 433 439
37. M Varterasian D Eilender R Mohammad B Chen K Hulburd D Rodriguez J Pluda M Valdivieso A Al-Katib 1996 Phase I trial of bryostatin 1 in relapsed lymphoma and CLL Proc Am Soc Clin Oncol 15 481 (Abstr # 1526)
38. S Weitman AM Langevin RL Berkow PJ Thomas CA Hurwitz AS Kraft AL Dubowy DL Smith M Bernstein 1999 A phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study Clin Cancer Res 5 2344 2348 (Pubitemid 29437312)
39. WHO (1979) Handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48
40. R Zhang HJ Muller K Kielassa F Marks M Gschwendt 1994 Partial purification of a type eta protein kinase C from murine brain: separation from other protein kinase C isoenzymes and characterization Biochem J 304 641 647
41. M Zhao MA Rudek P He BD Smith SD Baker 2005 Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry Anal Biochem 33 143 148 (Pubitemid 40092790)